Xeris Biopharma sees FY26 revenue $375M-$390M, consensus $368M

Sees FY26 adjusted EBITDA to increase in total dollars compared to FY25. “Our exceptional results in 2025 reflect the strength of our business and set the stage for our future,” said Steve Pieper, CFO. “As we look ahead to 2026, we will build on the strong momentum across our enterprise and expect total revenue to range from approximately $375 million to $390 million, representing more than 30% growth at the midpoint. This outlook will further strengthen our balance sheet, which will create even more financial flexibility to drive value in both the near and long term.”